Amreen Husain
About
Amreen Husain is a scholar working on Reproductive Medicine, Obstetrics and Gynecology and Oncology.
According to data from OpenAlex, Amreen Husain has authored 74 papers receiving a total of 8.2k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Reproductive Medicine, 30 papers in Obstetrics and Gynecology and 23 papers in Oncology. Recurrent topics in Amreen Husain's work include Ovarian cancer diagnosis and treatment (38 papers), Endometrial and Cervical Cancer Treatments (26 papers) and Uterine Myomas and Treatments (10 papers). Amreen Husain is often cited by papers focused on Ovarian cancer diagnosis and treatment (38 papers), Endometrial and Cervical Cancer Treatments (26 papers) and Uterine Myomas and Treatments (10 papers). Amreen Husain collaborates with scholars based in United States, Switzerland and France. Amreen Husain's co-authors include Luciana Molinero, Peter Schmid, Hiroji Iwata, Véronique Dièras, Sherene Loi, Sylvia Adams, Eric P. Winer, Jane Yuet Ching Hui, Carlos H. Barrios and Leisha A. Emens and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and JNCI Journal of the National Cancer Institute.
In The Last Decade
Amreen Husain
72 papers receiving 8.0k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Amreen Husain United States | 32 | 4.7k | 2.5k | 1.7k | 1.7k | 1.5k | 74 | 8.2k | ||
| Antonio González-Martı́n Spain | 40 | 4.1k 0.9× | 3.5k 1.4× | 1.1k 0.7× | 1.7k 1.0× | 1.4k 0.9× | 307 | 7.5k | ||
| Alexandra Léary France | 38 | 3.5k 0.7× | 2.6k 1.0× | 973 0.6× | 2.4k 1.4× | 2.0k 1.3× | 280 | 7.5k | ||
| Helen Mackay Canada | 41 | 2.9k 0.6× | 2.2k 0.9× | 1.2k 0.7× | 1.8k 1.1× | 2.9k 1.9× | 185 | 7.1k | ||
| Michael W. Sill United States | 36 | 2.4k 0.5× | 2.6k 1.0× | 1.1k 0.7× | 2.4k 1.4× | 2.0k 1.3× | 110 | 6.2k | ||
| Mansoor Raza Mirza Denmark | 34 | 2.6k 0.6× | 3.6k 1.4× | 620 0.4× | 2.4k 1.4× | 1.3k 0.9× | 228 | 6.4k | ||
| Werner Meier Germany | 32 | 3.3k 0.7× | 3.2k 1.2× | 634 0.4× | 866 0.5× | 1.6k 1.1× | 166 | 5.8k | ||
| Paul DiSilvestro United States | 33 | 2.0k 0.4× | 3.9k 1.5× | 700 0.4× | 2.6k 1.6× | 1.3k 0.9× | 159 | 6.4k | ||
| Mark F. Brady United States | 42 | 3.7k 0.8× | 8.4k 3.3× | 1.6k 1.0× | 3.9k 2.3× | 2.0k 1.3× | 111 | 12.0k | ||
| Kenneth D. Swenerton Canada | 26 | 2.2k 0.5× | 2.3k 0.9× | 598 0.4× | 1.2k 0.7× | 1.2k 0.8× | 55 | 4.6k | ||
| Kathleen M. Darcy United States | 39 | 1.8k 0.4× | 1.9k 0.7× | 641 0.4× | 1.3k 0.8× | 2.1k 1.4× | 174 | 5.1k |
Countries citing papers authored by Amreen Husain
Since
Specialization
Citations
This map shows the geographic impact of Amreen Husain's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amreen Husain with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amreen Husain more than expected).
Fields of papers citing papers by Amreen Husain
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Amreen Husain. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amreen Husain. The network helps show where Amreen Husain may publish in the future.
Co-authorship network of co-authors of Amreen Husain
This figure shows the co-authorship network connecting the top 25 collaborators of Amreen Husain. A scholar is included among the top collaborators of Amreen Husain based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amreen Husain. Amreen Husain is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Husain, Amreen, et al.. (2023). Disseminated Coccidioidomycosis in a Patient With Acute Promyelocytic Leukemia and Suspected Differentiation Syndrome. A5328–A5328.
2.
Emens, Leisha A., Luciana Molinero, Sherene Loi, et al.. (2021). Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study. JNCI Journal of the National Cancer Institute. 113(8). 1005–1016.
3.
Schmid, Peter, Hope S. Rugo, Sylvia Adams, et al.. (2019). Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Oncology. 21(1). 44–59.
4.
Husain, Amreen, Yan Wang, Lars Hanker, et al.. (2016). Independent radiologic review of AURELIA, a phase 3 trial of bevacizumab plus chemotherapy for platinum-resistant recurrent ovarian cancer. Gynecologic Oncology. 142(3). 465–470.
5.
Birrer, Michael J., YounJeong Choi, Mark F. Brady, et al.. (2015). Retrospective analysis of candidate predictive tumor biomarkers (BMs) for efficacy in the GOG-0218 trial evaluating front-line carboplatin–paclitaxel (CP) ± bevacizumab (BEV) for epithelial ovarian cancer (EOC).. Journal of Clinical Oncology. 33(15_suppl). 5505–5505.
6.
Aghajanian, Carol, Stephanie V. Blank, Barbara A. Goff, et al.. (2012). OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer. Journal of Clinical Oncology. 30(17). 2039–2045.
7.
Aghajanian, Carol, Lawrence R. Nycum, Barbara A. Goff, et al.. (2012). Updated Overall Survival Analysis in Oceans, a Randomized Phase 3 Trial of Gemcitabine (G) + Carboplatin (C) and Bevacizumab (BV) or Placebo (PL) Followed by BV or PL in Platinum-Sensitive Recurrent Epithelial Ovarian (ROC), Primary Peritoneal (PPC), or Fallopian Tube Cancer (FTC). Annals of Oncology. 23. ix319–ix319.
8.
Aghajanian, Carol, Stephanie V. Blank, Barbara A. Goff, et al.. (2012). An updated safety analysis of OCEANS, a randomized, double-blind, phase III trial of gemcitabine (G) and carboplatin (C) with bevacizumab (BV) or placebo (PL) followed by BV or PL to disease progression (PD) in patients with platinum-sensitive (Plat-S) recurrent ovarian cancer.. Journal of Clinical Oncology. 30(15_suppl). 5054–5054.
9.
Lavie, Ofer, Teri A. Longacre, Yakir Segev, & Amreen Husain. (2009). Ovarian Carcinosarcomas Associated With Prolonged Use of Tamoxifen: Case Reports. International Journal of Gynecological Cancer. 19(9). 1521–1523.
10.
Chan, John K., Daniel S. Kapp, Michael K. Cheung, et al.. (2008). Prognostic factors and risk of extrauterine metastases in 3867 women with grade 1 endometrioid corpus cancer. American Journal of Obstetrics and Gynecology. 198(2). 216.e1–216.e5.
11.
Yu, Xun, Joshua G. Cohen, Hrishikesh Deshmukh, et al.. (2008). The association of serial ultrasounds and CA125 prior to diagnosis of ovarian cancer—Do they improve early detection?. Gynecologic Oncology. 111(2). 385–386.
12.
Ueda, Stefanie, Daniel S. Kapp, Michael K. Cheung, et al.. (2008). Trends in demographic and clinical characteristics in women diagnosed with corpus cancer and their potential impact on the increasing number of deaths. American Journal of Obstetrics and Gynecology. 198(2). 218.e1–218.e6.
13.
Chan, John K., Elizabeth Munro, Michael K. Cheung, et al.. (2007). Association of Lymphadenectomy and Survival in Stage I Ovarian Cancer Patients. Obstetrics and Gynecology. 109(1). 12–19.
14.
Tran, Phuoc T., Zheng Su, Wendy Hara, et al.. (2007). Long-Term Survivors Using Intraoperative Radiotherapy for Recurrent Gynecologic Malignancies. International Journal of Radiation Oncology*Biology*Physics. 69(2). 504–511.
15.
Husain, Amreen, et al.. (2007). A prospective study of the accuracy of 18Fluorodeoxyglucose positron emission tomography (18FDG PET) in identifying sites of metastasis prior to pelvic exenteration. Gynecologic Oncology. 106(1). 177–180.
16.
Liou, Wen‐Shiung, Chad A. Hamilton, Michael K. Cheung, et al.. (2006). Outcomes of women with metachronous breast and ovarian carcinomas. Gynecologic Oncology. 103(1). 190–194.
17.
Chan, John K., Michael K. Cheung, Amreen Husain, et al.. (2006). Patterns and Progress in Ovarian Cancer Over 14 Years. Obstetrics and Gynecology. 108(3, Part 1). 521–528.
18.
Husain, Amreen, Paul Sabbatini, David R. Spriggs, et al.. (1999). Phase II Trial of Intraperitoneal Cisplatin and Mitoxantrone in Patients with Persistent Ovarian Cancer. Gynecologic Oncology. 73(1). 96–101.
19.
Husain, Amreen, Néstor Rosales, Gary K. Schwartz, & D R Spriggs. (1998). Lisofylline Sensitizes p53 Mutant Human Ovarian Carcinoma Cells to the Cytotoxic Effects ofcis-Diamminedichloroplatinum(II). Gynecologic Oncology. 70(1). 17–22.
20.
Husain, Amreen, Gang He, E. S. Venkatraman, & D R Spriggs. (1998). BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II).. PubMed. 58(6). 1120–3.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Antonio González-Martı́n Breakdown of academic impact, for papers by Alexandra Léary Breakdown of academic impact, for papers by Helen Mackay Breakdown of academic impact, for papers by Michael W. Sill Breakdown of academic impact, for papers by Mansoor Raza Mirza Breakdown of academic impact, for papers by Werner Meier Breakdown of academic impact, for papers by Paul DiSilvestro Breakdown of academic impact, for papers by Mark F. Brady Breakdown of academic impact, for papers by Kenneth D. Swenerton Breakdown of academic impact, for papers by Kathleen M. Darcy